STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

Trial Profile

STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Faricimab (Primary) ; Ranibizumab
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms STAIRWAY
  • Sponsors Roche
  • Most Recent Events

    • 30 Oct 2018 According to a Roche media release, based on the STAIRWAY data, a global phase III programme for faricimab in neovascular age related macular degeneration (nAMD) is anticipated to commence in 2019.
    • 29 Oct 2018 Results published in a Roche Media Release.
    • 26 Oct 2018 Positive results of the study were presented as a late-breaking oral presentation during the 2018 American Academy of Ophthalmologys (AAO) Annual Meeting in Chicago, Illinois, United States, according to a Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top